Latest Ratios: P/E Ratio 146.7x · EV/EBITDA 106.9x · ROE 5.1%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.4B | $1.9B | $2.8B | $1.7B | $1.2B | $1.8B | $1.5B | $769M | $700M | $182M | $69M |
| Enterprise Value | $2.4B | $1.9B | $2.9B | $1.7B | $1.2B | $1.8B | $1.5B | $770M | $682M | $172M | $56M |
| P/E Ratio → | 146.72 | 112.53 | 274.55 | — | — | — | 509.57 | — | — | — | — |
| P/S Ratio | 8.68 | 6.79 | 11.96 | 8.58 | 7.55 | 11.69 | 11.76 | 6.52 | 7.71 | 2.84 | 1.27 |
| P/B Ratio | 6.89 | 5.29 | 9.72 | 7.50 | 6.46 | 10.71 | 10.87 | 6.92 | 6.85 | 8.06 | 2.80 |
| P/FCF | 96.88 | 75.77 | — | 217.32 | 123.02 | 86.45 | 97.69 | — | — | — | — |
| P/OCF | 46.19 | 36.12 | 48.79 | 47.99 | 70.19 | 62.89 | 83.09 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.78 | 12.06 | 8.68 | 7.53 | 11.58 | 11.92 | 6.53 | 7.51 | 2.69 | 1.04 |
| EV / EBITDA | 106.93 | 83.61 | 285.55 | — | — | — | 311.20 | — | — | — | — |
| EV / EBIT | 216.93 | 98.94 | 257.28 | — | — | — | 485.16 | — | — | — | — |
| EV / FCF | — | 75.69 | — | 219.75 | 122.67 | 85.60 | 99.01 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.4% | 74.4% | 72.6% | 68.6% | 66.8% | 67.9% | 67.8% | 68.1% | 64.6% | 52.5% | 47.9% |
| Operating Margin | 4.0% | 4.0% | 1.9% | -3.3% | -10.4% | -5.0% | 1.9% | -9.5% | -4.3% | -23.4% | -35.4% |
| Net Profit Margin | 6.0% | 6.0% | 4.4% | -1.6% | -10.2% | -4.8% | 2.3% | -8.2% | -9.0% | -27.0% | -36.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.1% | 5.1% | 4.0% | -1.5% | -9.2% | -4.9% | 2.3% | -9.1% | -13.0% | -73.2% | -83.5% |
| ROA | 3.6% | 3.6% | 2.6% | -1.0% | -6.5% | -3.3% | 1.6% | -7.1% | -9.4% | -33.5% | -47.2% |
| ROIC | 2.5% | 2.5% | 1.2% | -2.2% | -7.5% | -3.8% | 1.3% | -8.6% | -6.1% | -90.7% | -148.2% |
| ROCE | 2.7% | 2.7% | 1.3% | -2.4% | -7.5% | -3.9% | 1.5% | -9.5% | -5.4% | -38.8% | -66.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.28 | 0.28 | 0.34 | 0.39 | 0.25 | 0.29 | 0.40 | 0.25 | — | 0.76 | 0.41 |
| Debt / EBITDA | 4.39 | 4.39 | 9.86 | — | — | — | 11.21 | — | — | — | — |
| Net Debt / Equity | — | -0.01 | 0.08 | 0.08 | -0.02 | -0.11 | 0.15 | 0.01 | -0.18 | -0.43 | -0.52 |
| Net Debt / EBITDA | -0.08 | -0.08 | 2.43 | — | — | — | 4.14 | — | — | — | — |
| Debt / FCF | — | -0.07 | — | 2.43 | -0.35 | -0.86 | 1.32 | — | — | — | — |
| Interest Coverage | 12.17 | 12.17 | 18.12 | -2.95 | -42.68 | -1894.50 | 508.33 | -1207.13 | -3.70 | -14.62 | -61.31 |
Net cash position: cash ($100M) exceeds total debt ($98M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.03 | 5.03 | 4.23 | 4.49 | 4.99 | 6.08 | 5.50 | 5.64 | 7.62 | 3.86 | 3.48 |
| Quick Ratio | 4.68 | 4.68 | 3.89 | 4.21 | 4.56 | 5.57 | 5.08 | 5.30 | 7.38 | 3.57 | 3.21 |
| Cash Ratio | 2.80 | 2.80 | 2.31 | 2.39 | 3.19 | 3.97 | 3.37 | 3.52 | 5.61 | 2.05 | 1.79 |
| Asset Turnover | — | 0.57 | 0.55 | 0.56 | 0.60 | 0.64 | 0.60 | 0.77 | 0.77 | 1.17 | 1.12 |
| Inventory Turnover | 4.02 | 4.02 | 3.75 | 4.73 | 3.41 | 3.75 | 4.27 | 5.51 | 9.04 | 8.00 | 8.12 |
| Days Sales Outstanding | — | 111.82 | 94.43 | 107.84 | 103.35 | 87.49 | 101.42 | 99.63 | 94.22 | 104.32 | 114.72 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.7% | 0.9% | 0.4% | — | — | — | 0.2% | — | — | — | — |
| FCF Yield | 1.0% | 1.3% | — | 0.5% | 0.8% | 1.2% | 1.0% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $52M | $52M | $48M | $47M | $46M | $47M | $44M | $40M | $33M | $23M |
Elective procedure demand sensitivity
Based on reported figures, VCEL trades at a forward P/E of 97.92, which suggests that investors are pricing the company as a de-risked commercial platform rather than a speculative biotech entity, despite the inherent volatility in its quarterly earnings and high P/S multiple of 8.55.
The elevated valuation multiples appear to be driven by the company's unique position as a profitable, pure-play cellular therapy provider with significant barriers to entry. Investors should monitor whether the current growth trajectory justifies these multiples, as any deceleration in the biopsy-to-implant conversion rate could lead to a significant compression in the stock's premium pricing.
According to quarterly data, ROIC has fluctuated between -3.0% and 5.0% over the last ten quarters, indicating that the company is still in the early stages of compounding returns on its invested capital as it scales its specialized manufacturing infrastructure and expands its surgeon network.
The inconsistency in ROIC suggests that the company's profitability is highly sensitive to facility utilization rates and the timing of commercial launches. Future returns on capital will likely depend on the company's ability to maintain high gross margins while simultaneously achieving operating leverage through increased volume in its core MACI franchise.
As reported in financial statements, the cash conversion cycle has shown significant variance, ranging from 33 to 106 days, which highlights the logistical challenges inherent in managing a patient-specific, vein-to-vein supply chain that requires precise coordination between surgeons and manufacturing facilities.
The fluctuations in DSO and DIO suggest that the company's working capital efficiency is subject to the timing of surgical procedures and inventory management for specialized biological reagents. Investors should interpret these metrics as a reflection of the operational complexity of the business model rather than a sign of deteriorating customer credit quality.
Based on recent balance sheet data, VCEL maintains a conservative debt-to-equity ratio of 0.28, which provides the company with significant financial flexibility to fund its ongoing commercial expansion and infrastructure investments without the immediate pressure of high interest service obligations.
The company's minimal reliance on debt appears to be a strategic choice that insulates it from interest rate volatility, allowing management to focus on long-term growth initiatives. This healthy leverage profile warrants further investigation into whether the company will eventually utilize its balance sheet capacity to pursue inorganic growth opportunities in the regenerative medicine space.
The market frequently misapplies standard biotech valuation metrics to VCEL, failing to account for the fact that the company operates more like a high-end specialized logistics firm than a traditional drug developer with a binary clinical trial risk profile.
Using traditional P/E or EV/EBITDA ratios without adjusting for the non-cash impact of stock-based compensation and the timing mismatch of revenue recognition obscures the true earning power of the business. Analysts should instead focus on the biopsy-to-implant conversion rate and free cash flow generation as more reliable indicators of the company's underlying commercial health.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VCEL stock.
Vericel Corporation's current P/E ratio is 146.7x. The historical average is 112.5x. This places it at the 100th percentile of its historical range.
Vericel Corporation's current EV/EBITDA is 106.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 83.6x.
Vericel Corporation's return on equity (ROE) is 5.1%. The historical average is -78.8%.
Based on historical data, Vericel Corporation is trading at a P/E of 146.7x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Vericel Corporation has 74.4% gross margin and 4.0% operating margin.
Vericel Corporation's Debt/EBITDA ratio is 4.4x, indicating high leverage. A ratio above 4x may signal elevated financial risk.